Current concepts of immune based treatments for patients with HCC: From basic science to novel treatment approaches

Gut

Volumn 64, Issue 5, 2015, Pages 842-848

  Greten, Tim F ^a   Wang, Xin W ^a   Korangy, Firouzeh ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ALPHA INTERFERON; ANTIBODY; ANTISENSE OLIGONUCLEOTIDE; CD137 ANTIBODY; CD40 LIGAND; INTERLEUKIN 15; MICRORNA; NIVOLUMAB; OX40 ANTIBODY; PD L1 ANTIBODY; PEXASTIMOGENE DEVACIREPVEC; SORAFENIB; STAT3 PROTEIN; TICILIMUMAB; UNCLASSIFIED DRUG; CANCER VACCINE;

ABLATION THERAPY; ADJUVANT THERAPY; ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ARTICLE; ARTIFICIAL EMBOLISM; CANCER GENE THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CRYOTHERAPY; CYTOKINE INDUCED KILLER CELL; DENDRITIC CELL; EXPERIMENTAL ANIMAL; GAMMA DELTA T LYMPHOCYTE; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; LIVER CELL CARCINOMA; MICROWAVE THERAPY; MOLECULAR GENETICS; MULTICENTER STUDY (TOPIC); NATURAL KILLER CELL; NONHUMAN; ONCOLYTIC VIROTHERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TUMOR IMMUNITY; ANIMAL; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL (TOPIC); DISEASE MODEL; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOTHERAPY; LIVER NEOPLASMS; PROCEDURES; TRANSLATIONAL RESEARCH; TUMOR REGRESSION;

ANIMALS; CANCER VACCINES; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; LIVER NEOPLASMS; NEOPLASM REGRESSION, SPONTANEOUS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84928797772     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-307990     Document Type: Article

References (112)

1. Theise ND. World cancer report 2014. IARC, 2014.
2. European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-43.
3. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-99.
4. Taniguchi K, Karin M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol 2014;26:54-74.
5. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997;336:1855-9.
6. Korangy F, Höchst B, Manns MP, et al. Immune responses in hepatocellular carcinoma. Dig Dis 2010;28:150-4.
7. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
8. Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. Best Pract Res Clin Gastroenterol 2014;28:753-70.
9. Iwanaga T. Studies on cases of spontaneous regression of cancer in Japan in 2011, and of hepatic carcinoma, lung cancer and pulmonary metastases in the world between 2006 and 2011. Gan To Kagaku Ryoho 2013;40:1475-87.
10. Epstein RJ, Leung TW. Reversing hepatocellular carcinoma progression by using networked biological therapies. Clin Cancer Res 2007;13:11-17.
11. Kumar A, Le DT. Hepatocellular Carcinoma Regression After Cessation of Immunosuppressive Therapy. J Clin Oncol. Published Online First: 22 Sep 2014. doi:10.1200/JCO.2013.51.4067
12. Castro FA, Liu X, Försti A, et al. Increased risk of hepatobiliary cancers after hospitalization for autoimmune disease. Clin Gastroenterol Hepatol 2014;12:1038-45.e7.
13. Okuma K, Yamashita H, Niibe Y, et al. Abscopal effect of radiation on lung metastases of hepatocellular carcinoma: a case report. J Med Case Rep 2011;5:111.
14. Nakanishi M, Chuma M, Hige S. Abscopal Effect on Hepatocellular Carcinoma. Am J Gastroenterol 2008;103:1320-1.
15. Ohba K, Omagari K, Nakamura T, et al. Abscopal regression of hepatocellular carcinoma after radiotherapy for bone metastasis. Gut 1998;43:575-7.
16. Nam SW, Han J-Y, Kim JI, et al. Spontaneous regression of a large hepatocellular carcinoma with skull metastasis. J Gastroenterol Hepatol 2005;20:488-92.
17. Mochizuki T, Takehara Y, Nishimura T, et al. Regression of hepatocellular carcinoma. AJR Am J Roentgenol 1991;156:868-9.
18. Hu K-Q. Advances in clinical application of cryoablation therapy for hepatocellular carcinoma and metastatic liver tumor. J Clin Gastroenterol 2014;48:830-6.
19. Zhou L, Wang C-P, Lu Y-Y, et al. Decrease in size of non-treated lesions after cryoablation for hepatocellular carcinoma. Hepatogastroenterology 2012;59:252-4.
20. Greten TF, Korangy F. Radiofrequency ablation for the treatment of HCC-maybe much more than simple tumor destruction? J Hepatol 2010;53:775-6.
21. Chu KF, Dupuy DE. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer 2014;14:199-208.
22. Dromi SA, Walsh MP, Herby S, et al. Radiofrequency ablation induces antigen-presenting cell infiltration and amplification of weak tumor-induced immunity1. Radiology 2009;251:58-66.
23. Greten TF, Duffy AG, Korangy F. Hepatocellular carcinoma from an immunologic perspective. Clin Cancer Res 2013;19:6678-85.
24. Knolle PA, Thimme R. Hepatic immune regulation and its involvement in viral hepatitis infection. Gastroenterology 2014;146:1193-207.
25. Jacob AI, Goldberg PK, Bloom N, et al. Endotoxin and bacteria in portal blood. Gastroenterology 1977;72:1268-70.
26. Tiegs G, Lohse AW. Immune tolerance: what is unique about the liver. J Autoimmun 2010;34:1-6.
27. Ormandy LA, Hillemann T, Wedemeyer H, et al. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 2005;65:2457-64.
28. Gao Q, Qiu SJ, Fan J, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007;25:2586-93.
29. Fu J, Xu D, Liu Z, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007;132:2328-39.
30. Greten TF, Ormandy LA, Fikuart A, et al. Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC. J Immunother 2010;33:211-18.
31. Talmadge JE, Gabrilovich D. History of myeloid-derived suppressor cells. Nat Rev Cancer 2013;13:7752.
32. Hoechst B, Ormandy LA, Ballmaier M, et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3 (+) T cells. Gastroenterology 2008;135:234-43.
33. Kapanadze T, Gamrekelashvili J, Ma C, et al. Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma. J Hepatol 2013;59:1007-13.
34. Duffy AG, Greten TF. Immunological off-target effects of standard treatments in gastrointestinal cancers. Ann Oncol 2014;25:24-32.
35. Qin H, Lerman B, Sakamaki I, et al. Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice. Nat Med 2015;20:676-81.
36. Sun X, Zhang J, Wang L, et al. Growth inhibition of human hepatocellular carcinoma cells by blocking STAT3 activation with decoy-ODN. Cancer Lett 2008;262:201-13.
37. Vasquez-Dunddel D, Pan F, Zeng Q, et al. STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J Clin Invest 2013;123:1580-9.
38. Kujawski M, Kortylewski M, Lee H, et al. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Investig 2008;118:3367-77.
39. Kortylewski M, Yu H. Role of Stat3 in suppressing anti-tumor immunity. Curr Opin Immunol 2008;20:228-33.
40. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009;9:798-809.
41. Sui Q, Zhang J, Sun X, et al. NK cells are the crucial antitumor mediators when STAT3-mediated immunosuppression is blocked in hepatocellular carcinoma. J Immunol 2014;193:2016-23.
42. Zhao F, Hoechst B, Gamrekelashvili J, et al. Human CCR4+CCR6+Th17 Cells Suppress Autologous CD8+ T Cell Responses. J Immunol 2012;188:6055-62.
43. Wu J, Du J, Liu L, et al. Elevated pretherapy serum IL17 in primary hepatocellular carcinoma patients correlate to increased risk of early recurrence after curative hepatectomy. PLoS ONE 2012;7:e50035.
44. Ma S, Cheng Q, Cai Y, et al. IL-17A produced by γd T cells promotes tumor growth in hepatocellular carcinoma. Cancer Res 2014;74:1969-82.
45. Budhu A, Forgues M, Ye Q-H, et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006;10:99-111.
46. Hoshida Y, Villanueva A, Kobayashi M, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008;359:1995-2004.
47. Ji J, Shi J, Budhu A, et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 2009;361:1437-47.
48. Ji J, Yu L, Yu Z, et al. Development of a miR-26 companion diagnostic test for adjuvant interferon-alpha therapy in hepatocellular carcinoma. Int J Biol Sci 2013;9:303-12.
49. Chew V, Chen J, Lee D, et al. Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut 2012;61:427-38.
50. Hou J, Zhou Y, Zheng Y, et al. Hepatic RIG-I predicts survival and interferon-α therapeutic response in hepatocellular carcinoma. Cancer Cell 2014;25:49-63.
51. Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011;8:151-60.
52. Hipp MM, Hilf N, Walter S, et al. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 2008;111:5610-20.
53. Molhoek KR, McSkimming CC, Olson WC, et al. Apoptosis of CD4+CD25high T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2. Cancer Immunol Immunother 2008;58:867-76.
54. Busse A, Asemissen AM, Nonnenmacher A, et al. Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma. Eur J Cancer 2011;47:690-6.
55. Cabrera R, Ararat M, Xu Y, et al. Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma. Cancer Immunol Immunother 2013;62:737-46.
56. Desar IM, Jacobs JH, Hulsbergen-Vandekaa CA, et al. Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients. Int J Cancer 2011;129:507-12.
57. Wang Q, Yu T, Yuan Y, et al. Sorafenib reduces hepatic infiltrated regulatory T cells in hepatocellular carcinoma patients by suppressing TGF-beta signal. J Surg Oncol 2013;107:422-7.
58. Chen Y, Huang Y, Reiberger T, et al. Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. Hepatology 2014;59:1435-47.
59. Krusch M, Salih J, Schlicke M, et al. The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro. J Immunol 2009;183:8286-94.
60. Mulder SF, Jacobs JFM, Olde Nordkamp MAM, et al. Cancer patients treated with Sunitinib or Sorafenib have sufficient antibody and cellular immune responses to warrant influenza vaccination. Clin Cancer Res 2011;17:4541-9.
61. Yang X, Lu P, Ishida Y, et al. Attenuated liver tumor formation in the absence of CCR2 with a concomitant reduction in the accumulation of hepatic stellate cells, macrophages and neovascularization. Int J Cancer 2006;118:335-45.
62. Belnoue E, Guettier C, Kayibanda M, et al. Regression of established liver tumor induced by monoepitopic peptide-based immunotherapy. J Immunol 2004;173:4882-8.
63. Schneider C, Teufel A, Yevsa T, et al. Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer. Gut 2012;61:1733-43.
64. Zender L, Zuber J, Lowe SW. SnapShot: Genetic Mouse Models of Cancer. Cell 2007;129:838.e1-e2.
65. Zender L, Xue W, Cordon CC, et al. Generation and analysis of genetically defined liver carcinomas derived from bipotential liver progenitors. Cold Spring Harb Symp Quant Biol 2005;70:251-61.
66. Stauffer JK, Scarzello AJ, Andersen JB, et al. Coactivation of AKT and {beta}-Catenin in Mice Rapidly Induces Formation of Lipogenic Liver Tumors. Cancer Res 2011;71:2718-27.
67. Ney JT, Schmidt T, Kurts C, et al. Autochthonous liver tumors induce systemic T cell tolerance associated with T cell receptor down-modulation. Hepatology 2009;49:471-81.
68. Morales-Kastresana A, Sanmamed MF, Rodriguez I, et al. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model. Clin Cancer Res 2013;19:6151-62.
69. Willimsky G, Schmidt K, Loddenkemper C, et al. Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance. J Clin Invest 2013;123:1032-43.
70. Kornek M, Raskopf E, Guetgemann I, et al. Combination of systemic thioacetamide (TAA) injections and ethanol feeding accelerates hepatic fibrosis in C3H/He mice and is associated with intrahepatic up regulation of MMP-2, VEGF and ICAM-1. J Hepatol 2006;45:370-6.
71. Hebbard L, George J. Animal models of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2011;8:35-44.
72. Nakagawa H, Umemura A, Taniguchi K, et al. ER stress cooperates with hypernutrition to Trigger TNF-dependent spontaneous HCC development. Cancer Cell 2014;26:331-43.
73. Wolf MJ, Adili A, Piotrowitz K, et al. Metabolic activation of intrahepatic CD8(+) T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. Cancer Cell 2014;26:549-64.
74. Cany J, Barteau B, Tran L, et al. AFP-specific immunotherapy impairs growth of autochthonous hepatocellular carcinoma in mice. J Hepatol 2011;54:115-21.
75. Hong Y, Peng Y, Guo SZ, et al. Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma. Hepatology 2014;59:1448-58.
76. Gauttier V, Judor J-P, Le Guen V, et al. Agonistic anti-CD137 antibody treatment leads to anti-tumour response in mice with liver cancer. Int J Cancer 2014;135:2857-67.
77. Brinkhoff B, Ostroumov D, Heemcke J, et al. Microsphere priming facilitates induction of potent therapeutic T-cell immune responses against autochthonous liver cancers. Eur J Immunol 2014;44:1213-24.
78. Cheng L, Du X, Wang Z, et al. Hyper-IL-15 suppresses metastatic and autochthonous liver cancers by promoting tumor-specific CD8+ T cell responses. J Hepatol 2014;61:1297-303.
79. Gao H, Li K, Tu H, et al. Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular Carcinoma. Clin Cancer Res 2014;20:6418-28.
80. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368:1509-18.
81. Maus MV, Grupp SA, Porter DL, et al. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 2014;123:2625-35.
82. Leboeuf C, Mailly L, Wu T, et al. In Vivo Proof of Concept of Adoptive Immunotherapy for Hepatocellular Carcinoma Using Allogeneic Suicide Gene-modified Killer Cells. Mol Ther 2013;22:634-44.
83. Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science 2013;339:1546-58.
84. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer. N Engl J Med 2012;366:2455-65.
85. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013;499:214-18.
86. Wolchok JD, Chan TA. Cancer: Antitumour immunity gets a boost. Nature 2014;515:496-8.
87. Sangro B, Gomez-Martin C, la Mata de M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 2013;59:81-8.
88. Hato T, Goyal L, Greten TF, et al. Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions. Hepatology 2014;60:1776-82.
89. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998;16:111-35.
90. Vonderheide RH, Glennie MJ. Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res 2013;19:1035-43.
91. Iida T, Shiba H, Misawa T, et al. Adenovirus-mediated CD40L gene therapy induced both humoral and cellular immunity against rat model of hepatocellular carcinoma. Cancer Sci 2008;99:2097-103.
92. Gonzalez-Carmona MA, Lukacs-Kornek V, Timmerman A, et al. CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo. Hepatology 2008;48:157-68.
93. Woller N, Knocke S, Mundt B, et al. Virus-induced tumor inflammation facilitates effective DC cancer immunotherapy in a Treg-dependent manner in mice. Journal of Clinical Investigation 2011;121:2570-82.
94. Heo J, Reid T, Ruo L, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 2013;19:329-36.
95. Chen Y, Yang D, Li S, et al. Development of a Listeria monocytogenes-based vaccine against hepatocellular carcinoma. Oncogene 2012;31:2140-52.
96. Woller N, Gürlevik E, Ureche C-I, et al. Oncolytic Viruses as Anticancer Vaccines. Front Oncol 2014;4.
97. Kwon O-J, Kim P-H, Huyn S, et al. A hypoxia-and {alpha}-fetoprotein-dependent oncolytic adenovirus exhibits specific killing of hepatocellular carcinomas. Clin Cancer Res 2010;16:6071-82.
98. Transgene. http://www.transgene.fr (accessed 31 Oct 2014).
99. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
100. Greten TF, Manns MP, Korangy F. Immunotherapy of hepatocellular carcinoma. J Hepatol 2006;45:868-78.
101. Greten TF, Manns MP, Korangy F. Immunotherapy of HCC. Rev Recent Clin Trials 2008;3:31-9.
102. Breous E, Thimme R. Potential of immunotherapy for hepatocellular carcinoma. J Hepatol 2011;54:830-4.
103. Nakamoto Y, Mizukoshi E, Tsuji H, et al. Combined therapy of transcatheter hepatic arterial embolization with intratumoral dendritic cell infusion for hepatocellular carcinoma: clinical safety. Clin Exp Immunol 2007;147:296-305.
104. Hao M-Z, Lin H-L, Chen Q, et al. Efficacy of transcatheter arterial chemoembolization combined with cytokine-induced killer cell therapy on hepatocellular carcinoma: a comparative study. Chin J Cancer 2010;29:172-7.
105. Huang Z-M, Li W, Li S, et al. Cytokine-induced Killer Cells in Combination With Transcatheter Arterial Chemoembolization and Radiofrequency Ablation for Hepatocellular Carcinoma Patients. J Immunother 2013;36:287-93.
106. Nakamoto Y, Mizukoshi E, Kitahara M, et al. Prolonged recurrence-free survival following OK432-stimulated dendritic cell transfer into hepatocellular carcinoma during transarterial embolization. Clin Exp Immunol 2011;163:165-77.
107. Cui J, Wang N, Zhao H, et al. Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma. Int J Cancer 2014;134:342-51.
108. Xie F, Zhang X, Li H, et al. Adoptive immunotherapy in postoperative hepatocellular carcinoma: a systemic review. PLoS ONE 2012;7:e42879.
109. Llosa NJ, Cruise M, Tam A, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 2015;5:43-51.
110. Brahmer JR. Harnessing the Immune System for the Treatment of Non-Small-Cell Lung Cancer. J Clin Oncol 2013;31:1021-8.
111. Le DT. Phase 2, randomized trial of GVAX pancreas and CRS-207 immunotherapy versus GVAX alone in patients with metastatic pancreatic adenocarcinoma: Updated results. J Clin Oncol;32(Suppl 3)-abstract177.
112. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15:7412-20.